title: New in vitro and in vivo models to evaluate antibiotic efficacy in Staphylococcus aureus prosthetic vascular graft infection.
abstract: OBJECTIVE
  Prosthetic vascular graft infection (PVGI) is an emerging disease, mostly caused by staphylococci, with limited data regarding efficacy of current antistaphylococcal agents. We aimed to assess the efficacy of different antibiotic regimens.
  
  
  METHODS
  Six different strains of MSSA and MRSA were used. We compared results of minimal biofilm inhibitory and eradicating concentrations (MBICs and MBECs) obtained with a Calgary Biofilm Pin Lid Device (CBPD) with those yielded by an original Dacron(®)-related minimal inhibitory and eradicating concentration measure model. We then used a murine model of Staphylococcus aureus vascular prosthetic material infection to evaluate efficacy of different antibiotic regimens: vancomycin and daptomycin combined or not with rifampicin for MRSA and the same groups with cloxacillin and cloxacillin combined with rifampicin for MSSA.
  
  
  RESULTS
  We demonstrated that classical measures of MBICs and MBECs obtained with a CPBD could overestimate the decrease in antibiotic susceptibility in material-related infections and that the nature of the support used might influence the measure of biofilm susceptibility, since results yielded by our Dacron(®)-related minimal eradicating assay were lower than those found with a plastic device. In our in vivo model, we showed that daptomycin was significantly more bactericidal than comparators for some strains of MRSA or MSSA but not for all. For the majority of strains, it was as efficient as comparators. The addition of rifampicin to daptomycin did not enhance daptomycin efficacy.
  
  
  CONCLUSIONS
  Despite the heterogeneity of results according to bacterial strains, these innovative models represent an option to better evaluate the in vitro efficacy of antibiotics on Dacron(®)-related biofilm S. aureus infections, and to screen different antibiotic regimens in a mouse model of PVGIs.
authors: Université Nantes, Faculté Médecine EA3826 Nantes, France CHU Rennes Infectious Diseases and Intensive Care Unit, Pontchaillou Hospital, 35033 Rennes Cedex, France CIC Inserm 1414, Rennes 1 University, Pontchaillou Hospital, 35033 Rennes Cedex, France matthieu.revest@chu-rennes.fr.
authors: M
authors: M
authors: Revest
authors: Université Nantes, Faculté Médecine EA3826 Nantes, France.
authors: C
authors: C
authors: Jacqueline
authors: Institut des Sciences Moléculaires Orsay, CNRS, Université Paris-Sud, 91405 Orsay, France.
authors: R
authors: R
authors: Boudjemaa
authors: Université Nantes, Faculté Médecine EA3826 Nantes, France.
authors: J
authors: J
authors: Caillon
authors: Université Nantes, Faculté Médecine EA3826 Nantes, France.
authors: V
authors: V
authors: Le Mabecque
authors: Université Nantes, Faculté Médecine EA3826 Nantes, France.
authors: A
authors: A
authors: Breteche
authors: Institut des Sciences Moléculaires Orsay, CNRS, Université Paris-Sud, 91405 Orsay, France.
authors: K
authors: K
authors: Steenkeste
authors: CHU Rennes Infectious Diseases and Intensive Care Unit, Pontchaillou Hospital, 35033 Rennes Cedex, France CIC Inserm 1414, Rennes 1 University, Pontchaillou Hospital, 35033 Rennes Cedex, France.
authors: P
authors: P
authors: Tattevin
authors: Université Nantes, Faculté Médecine EA3826 Nantes, France.
authors: G
authors: G
authors: Potel
authors: CHU Rennes Infectious Diseases and Intensive Care Unit, Pontchaillou Hospital, 35033 Rennes Cedex, France CIC Inserm 1414, Rennes 1 University, Pontchaillou Hospital, 35033 Rennes Cedex, France.
authors: C
authors: C
authors: Michelet
authors: Institut des Sciences Moléculaires Orsay, CNRS, Université Paris-Sud, 91405 Orsay, France.
authors: M P
authors: MP
authors: Fontaine-Aupart
authors: Université Nantes, Faculté Médecine EA3826 Nantes, France CHU Nantes, Infectious Diseases Unit, Hôtel Dieu, Nantes, France.
authors: D
authors: D
authors: Boutoille
mesh_terms: D000818:Animals; D000900:Anti-Bacterial Agents / Q000008:administration & dosage*; D018441:Biofilms / Q000187:drug effects; D017576:Daptomycin / Q000008:administration & dosage; D004195:Disease Models, Animal; D004359:Drug Therapy, Combination / Q000379:methods; D005260:Female; D051379:Mice; D008826:Microbial Sensitivity Tests; D008954:Models, Biological; D016459:Prosthesis-Related Infections / Q000188:drug therapy* / Q000382:microbiology; D012293:Rifampin / Q000008:administration & dosage; D013203:Staphylococcal Infections / Q000188:drug therapy* / Q000382:microbiology; D013211:Staphylococcus aureus / Q000187:drug effects* / Q000502:physiology; D016896:Treatment Outcome; D014640:Vancomycin / Q000008:administration & dosage
chemical_list: D000900:Anti-Bacterial Agents; D014640:Vancomycin; D017576:Daptomycin; D012293:Rifampin